$11.330
+0.713 (+6.29%)收盤時
FMC 資訊
FMC 事件
BofA Resumes Coverage of FMC with Neutral Rating and $12 Price Target
BofA resumed coverage of FMC with a Neutral rating and $12 price target. Along with Q2 results, FMC lowered its full-year outlook, which resets the back half sharply lower, though at about $425M implied second half EBITDA, the guidance sits below the roughly $480M consensus, the analyst tells investors.
Company Sees Q3 Revenue of $840M-$900M
Sees Q3 revenue $840M-$900M, consensus $952.56M. Sees Q3 adjusted EBITDA $120M-$130M. Says lower EBITDA and higher interest expense driving EPS guidance. Says lower revenue volumes driven by North America distributors shifting orders to Q4 to align purchases closer to timing of application. Says lower price, lower volume and foreign exchange headwind driving adjusted EBITDA guidance. Guidance taken from Q2 presentation slides.
Company Sees Q4 Revenue of $1.06B-$1.2B
Sees Q4 revenue $1.06B-$1.2B. Sees Q4 adjusted EBITDA $276M-$315M. Guidance taken from Q2 presentation slides.
FMC Reports Q2 Revenue of $867M
Reports Q2 revenue $867M, consensus $897.14M. "During the quarter, we completed several important actions that strengthened FMC's financial foundation and provide greater flexibility to execute our strategy," said Pierre Brondeau, chairman, chief executive officer and president. "With the strategic review now concluded, we have clarity on the path forward and remain focused on improving competitiveness, advancing our technology portfolio and positioning the company for long-term growth."
FY26 Revenue Guidance Cut to $3.5B-$3.7B
FY26 consensus $1.66. Cuts FY26 revenue, excluding India, to $3.5B-$3.7B from $3.6B-$3.8B, consensus $3.71B. Adjusted EBITDA lowered to a range of $620M-$680M, a decline of 23% at the midpoint. Free cash flow, which now includes the upfront licensing payment for rimisoxafen of $200M, increased to a range of $75M-$225M. Cites more challenging macro environment.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。